Amgen Inc.

The transcript from the Q4 2020 Amgen earnings call (February 2, 2021) does not mention any plans for new fundraising through debt or equity. Key points relevant to capital and financial strategy include: - Amgen acknowledges intense capital flow into the biopharma sector and emphasizes the importance of execution. - The company highlights a track record of quality and speed in innovation and capital deployment. - They focus on growing volumes and after-tax cash flows, aiming for operating margin growth. - Biosimilars are noted as a strong capital allocation area with competitive margins. - No explicit mention of plans for raising new capital via debt or equity financing in 2021 or the near future. - Emphasis on internal investment, productivity, digitization, and selective external investments without references to fundraising. In summary, Amgen appears focused on efficient internal capital use and strategic investments rather than announcing new debt or equity fundraising.

- Amgen plans to increase R&D investment in 2021, focusing on promising mid-stage pipeline candidates and long-term research strategies such as human genetics and induced proximity platforms (targeted protein degradation and multi-specific activity) (Page 1). - Continued strong allocation of capital to biosimilars, which remain a priority due to competitive margins and expertise, indicating ongoing financial commitment in this area (Page 3). - Investment in digital capabilities and automation to improve productivity and commercial model efficiency post-COVID (Page 6). - Strategic investment in expanding Otezla's global footprint, including promotional efforts in primary care and registration in new international markets such as Japan and Australia (Page 6). - Building capabilities and collaborations in human genetics and proteomics, including adding approximately 1 million subjects' data for drug target discovery and clinical trial design (Page 1).

- Expect continued volume growth from key products like Prolia, Otezla, Repatha, EVENITY, and innovative oncology portfolio. - Anticipate international expansion, including new market launches for Aimovig and biosimilars, growing sales outside the US beyond $6 billion. - Otezla expected to grow globally, with focus on expanding into mild to moderate psoriasis and increasing promotional efforts including primary care. - Biosimilar sales expected to grow, though offset by price declines due to competition. - Parsabiv sales forecast to decline 40-50% in 2021 due to reimbursement changes. - Aimovig volume growth of 21% reported; expect continued demand despite pandemic impacts. - Amid anticipated mid-single digit net selling price declines globally, overall revenue guidance for 2021 is $25.8 billion to $26.6 billion. - Digital commercial model enhancements aim to sustain sales force productivity post-COVID. - Investing in pipeline innovations (sotorasib, Tezepelumab) expected to contribute meaningfully to future revenue.

- Amgen projects 2021 revenue guidance of $25.8 billion to $26.6 billion. - Non-GAAP earnings per share (EPS) guidance for 2021 is $12.12 to $13.17 per share. - Operating expenses expected to grow about 7% year-over-year as investments in innovation and launches increase. - Operating margin anticipated to be roughly 50% in 2021. - Cost of sales expected to rise to about 17% of product sales due to product mix changes and higher royalties. - Continued volume-driven growth strategy with mid-single digit net selling price declines expected. - Investments planned for early and late-stage drug pipeline advancement, as well as digital transformation efforts. - Commitment to growing dividends, including a 10% increase in Q1 2021 dividend and up to $4 billion in opportunistic share repurchases. - Overall, Amgen expects sustained growth in revenues and non-GAAP EPS supported by new product launches and strong volume growth.

The provided transcript from Amgen’s Q4 2020 earnings call does not explicitly mention current or expected orderbook or pending orders details. However, relevant points that may relate to demand outlook or business expectations include: - Strong sales and earnings in 2020 driven by 15% volume growth across the portfolio. - Growth outside the US to more than $6 billion, with expanded presence in China and Japan. - Anticipated launch preparations and global submissions for sotorasib, a first-in-class KRAS G12C inhibitor. - Ongoing enrollment and data readouts in key clinical programs (e.g., sotorasib, tezepelumab). - Expansion and continued investment in commercial capabilities including digital channels to maintain competitive share. - Incremental growth opportunities in biosimilars despite price pressures. - Continued commercial rollout of recently acquired products (e.g., Otezla) with global market expansion. - Overall guidance suggest confidence in ongoing demand driven by innovative pipeline and portfolio expansion. No direct numerical orderbook or pending orders figures were disclosed on page 7 or adjacent pages.